The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study.

Slides:

Advertisements

Similar presentations

First author: Roman Adina Co-author: Andone Sebastian

Advertisements

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Discriminant Model for Cytologic Distinction of Large Cell Neuroendocrine Carcinoma from Small Cell Carcinoma of the Lung Rira Hoshi, CT, Noriyuki Furuta,

Algorithm for adenocarcinoma diagnosis in small biopsies and/or cytology. Step 1: When positive biopsies (fiberoptic bronchoscopy [FOB], transbronchial.

Primary cutaneous mucinous carcinoma of the breast

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

The 2015 World Health Organization Classification of Lung Tumors

Resection of a Giant Neuroblastoma Misdiagnosed as Atypical Mediastinal Carcinoid Eleftherios Chalvatzoulis, MD, Jeremias Wohlschlaeger, MD, Thomas Hager,

Large cell neuroendocrine carcinoma of the lung: a 10-year clinicopathologic retrospective study Massimiliano Paci, MD, Alberto Cavazza, MD, Valerio.

ALK FISH and IHC: You Cannot Have One without the Other

ΔNp63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit,

The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung Adi F. Gazdar, MD, Trisha K. Savage, MS, Jane.

Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease Andrew E. Hendifar,

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Neal I. Lindeman,

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Sclerosing Pneumocytoma with Lymph Node Metastasis

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Molecular Markers Help Characterize Neuroendocrine Lung Tumors

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

An Unusual Cause of Dysphagia with Bronchoesophageal Fistula

ITMIG Consensus Statement on the Use of the WHO Histological Classification of Thymoma and Thymic Carcinoma: Refined Definitions, Histological Criteria,

Ming-Sound Tsao, MD, FRCPC, William D

Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer Kyohei Masai, MD, Hiroyuki Sakurai,

Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production Ken Takezawa, MD, Isamu Okamoto, MD, PhD, Junya Fukuoka, MD, PhD,

Interpretation of Anti-ALK Immunohistochemistry Results

Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart William D. Travis, MD, Elisabeth Brambilla,

Keith M. Kerr, MBChB, FRCPath, Ming-Sound Tsao, MD, PhD, Andrew G

Intravascular Lymphoma as a Cause of Respiratory Failure

Small Cell Transformation and T790M Mutation as Coresistance Mechanisms for First- line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Reproducibility of Histopathological Diagnosis in Poorly Differentiated NSCLC: An International Multiobserver Study Erik Thunnissen, MD, PhD, Masayuki.

Pulmonary large cell carcinomas with neuroendocrine features are high-grade neuroendocrine tumors Akira Iyoda, MD, Kenzo Hiroshima, MD, Masayuki Baba,

Pulmonary Blastoma with Renal Metastasis Responds to Sorafenib

Histologic Transformation in NSCLC with PD-1 therapy

Adnan M. Al-Ayoubi, MD, Jonathan S. Ralston, MD, S

Radiologic Response to Neoadjuvant Treatment Predicts Histologic Response in Thymic Epithelial Tumors Geoffrey B. Johnson, MD, PhD, Marie Christine Aubry,

Mark L. Kayton, MD, Mai He, MD, PhD, Maureen F. Zakowski, MD, Andre L

Ritbune Prakobkit, MD, William Churk-Nam Auyeung, MD

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Lung Cancer Patients with Germline Mutations Detected by Next-Generation Sequencing and/or Liquid Biopsy Takehito Shukuya, MD, PhD, Sandipkumar Patel,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Large cell neuroendocrine carcinoma of the lung: A clinicopathologic study of eighty- seven cases Hidefumi Takei, MDa,b, Hisao Asamura, MDb, Arafumi Maeshima,

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

Discriminant Model for Cytologic Distinction of Large Cell Neuroendocrine Carcinoma from Small Cell Carcinoma of the Lung Rira Hoshi, CT, Noriyuki Furuta,

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Tracheal Mucoepidermoid Carcinoma

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs Patrick Micke,

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Carlie S. Sigel, MD, Andre L. Moreira, MD, PhD, William D

Primary Lung Cancer Presenting with Gastrointestinal Tract Involvement: Clinicopathologic and Immunohistochemical Features in a Series of 18 Consecutive.

Atypical Primary Epithelioid Hemangioendothelioma of the Heart

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Anu Dham, MD, Alexander M. Truskinovsky, MD, Arkadiusz Z

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

A Nonresponding Small Cell Lung Carcinoma

Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Biclonal Non-small Cell Lung Cancer in Disseminated Tumor Cells and Tissue Anna Puggina, MSc, Verena Kümmerlen, MD, Korinna Jöhrens-Leder, MD, Ulrich.

A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors Jules L. Derks, MD, Robert Jan.

Neuroendocrine Cancer of the Lung: A Diagnostic Puzzle

Volume 5, Issue 5, Pages (May 2019)

Analysis of Differentially Expressed Genes in Neuroendocrine Carcinomas of the Lung Chigusa Okubo, MS, Yuko Minami, MD, Ryota Tanaka, MD, Teruhito Uchihara,

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

Successful Treatment with Pemetrexed in a Patient with Mucinous Bronchioloalveolar Carcinoma: Long-Term Response Duration with Mild Toxicity Chiyuki.

Presentation transcript:

The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases Erik Thunnissen, MD, PhD, Alain C. Borczuk, MD, PhD, Douglas B. Flieder, MD, PhD, Birgit Witte, Ing., PhD, Mary Beth Beasley, MD, Jin-Haeng Chung, MD, Sanja Dacic, MD, Sylvie Lantuejoul, MD, PhD, Prudence A. Russell, MD, PhD, M.B.B.S., Michael den Bakker, MD, PhD, Johan Botling, MD, PhD, Elisabeth Brambilla, MD, PhD, Erienne de Cuba, MD, Kim R. Geisinger, MD, Kenzo Hiroshima, MD, PhD, Alberto M. Marchevsky, MD, Yuko Minami, MD, Andre Moreira, MD, Andrew G. Nicholson, MD, PhD, Akihiko Yoshida, MD, Ming- Sound Tsao, MD, Arne Warth, MD, PhD, Edwina Duhig, BMedSci, Gang Chen, MD, PhD, Yoshihiro Matsuno, MD, PhD, William D. Travis, MD, Kelly Butnor, MD, PhD, Wendy Cooper, MD, PhD, Mari Mino-Kenudson, MD, Noriko Motoi, MD, PhD, Claudia Poleri, MD, Giuseppe Pelosi, MD, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, Seena C. Aisner, MD, Yuichi Ishikawa, MD, Reinhard H. Buettner, MD, PhD, Naoto Keino, MA, Yasushi Yatabe, MD, PhD, Masayuki Noguchi, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 2, Pages 334-346 (February 2017) DOI: 10.1016/j.jtho.2016.12.004 Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 (A and B) Example of biopsy specimen with uniform diagnosis of SCLC in level 3 (hematoxylin and eosin stain; original magnification, ×10). (C) CD56 immunohistochemistry (IHC) staining with abundant membranous pattern (original magnification, ×40). (D) Chromogranin A IHC staining with dotlike cytoplasmic pattern (original magnification, ×40). (E) Synaptophysin IHC staining with diffuse cytoplasmic pattern (original magnification, ×40). (F) Strong MIB1 IHC staining in most tumor cell nuclei (original magnification, ×40). Journal of Thoracic Oncology 2017 12, 334-346DOI: (10.1016/j.jtho.2016.12.004) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Example of resection specimen with high agreement regarding diagnosis of LCNEC (level 3: 16 of 19 diagnoses were LCNEC and three of 19 were SCLC). (A and B) Hematoxylin and eosin stain (original magnification, ×40). (C) Synaptophysin IHC stain (original magnification, ×40). (D) MIB1 IHC with nuclear staining in most of the neoplastic nuclei (original magnification, ×40). Journal of Thoracic Oncology 2017 12, 334-346DOI: (10.1016/j.jtho.2016.12.004) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Example of biopsy specimen with uniform diagnosis of NSCLC in level 3. (A and B) Hematoxylin and eosin stain (original magnification, ×40). (C) CD56 IHC showing no staining (original magnification, ×40). (D) p40 IHC with abundant staining in most tumor cell nuclei (D, ×40). Journal of Thoracic Oncology 2017 12, 334-346DOI: (10.1016/j.jtho.2016.12.004) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Example of biopsy specimen with differential diagnostic scores (level 3: eight of 19 diagnoses were SCLC, eight of 19 were atypical carcinoid, and three of 19 were LCNEC). (A and B) Routine hematoxylin and eosin stain (original magnification, ×40). (C) CD56 IHC showing distinct membranous staining (original magnification, ×40). (D) Chromogranin A IHC with abundant cytoplasmic staining (original magnification, ×40). (E) Synaptophysin IHC with diffuse cytoplasmic staining (original magnification, ×40). (F) MIB1 IHC with nuclear staining in minority of tumor cell nuclei (original magnification, ×40). Note that low MIB1 favors atypical carcinoid. Journal of Thoracic Oncology 2017 12, 334-346DOI: (10.1016/j.jtho.2016.12.004) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Diagnostic flow diagram integrating morphologic and immunohistochemical (IHC) stains for the diagnosis (Dx) of neuroendocrine (NE) lung cancer. Note that if the flow diagram had been available during this study, the case in Figure 4 might have been favored to be a carcinoid on the basis of limited proliferative activity. (1) Fields are characteristic of carcinoma and cytokeratin positive. In tumors with diffuse growth, in addition to undifferentiated carcinoma (dissociation) and sarcomatoid carcinoma, also consider sarcoma and lymphoma. (2) The number of mitoses in 2 mm2. (3) If using a biopsy specimen, think of crushed carcinoid, especially with small regular nuclei with unclear chromatin, and slightly too much cytoplasm for SCLC. In addition NE IHC may be ++. (4) Dense chromatin equates to salt and pepper chromatin. (5) NE architecture may be focally present in whole tumor but usually absent in small biopsy specimens (especially bronchoscopic biopsy specimens), which is the reason why the WHO states that a Dx of large cell neuroendocrine carcinoma (LCNEC) is to be made only on the basis of a resection specimen. If the biopsy specimen fits with a Dx of LCNEC, suggest LCNEC as a possible Dx, remarking that this is difficult to establish on the basis of very small biopsy specimens. (6) Chromogranin A/synaptophysin staining is diffusely positive in carcinoid tumors, but chromogranin A is usually present only focally in SCLC/LCNEC; strong membranous CD56 staining is present in SCLC. (7) In the WHO classification of lung cancer, it is stated more or less arbitrarily that an atypical carcinoid (Atyp C) morphologic pattern with more than 10 mitoses per 2 mm2 should be called LCNEC. (8) Necrosis in carcinoids is usually dotlike (punctate). More than dotlike necrosis is usually seen in SCLC, LCNEC, and NSCLC. (9) In Atyp C, there are many apoptotic figures in contrast to the low number of mitoses. (10) NE morphologic features include rosettes, organoid nesting, formation of pseudorosettes, trabeculae, and palisading. (11) In NSCLC further analysis (FA) of architecture/IHC (e.g., TTF1, mucin), if TTF1 and mucin staining result is negative, consider undifferentiated large cell (null phenotype). (12) In FA, think of lymphoma, sarcoma, melanoma, metastasis breast, and other. (13) If discernible, there are many mitoses; in any case, there are many apoptotic figures. (14) In the case of a resection specimen, nonkeratinizing squamous cell carcinoma (SqCC); in the case of biopsy specimens, NSCLC favor nonkeratinizing SqCC; and on the basis of “in-between” cytoplasm, think of basaloid carcinoma. (15) The mitoses threshold is 25 according to Pelosi et al.21 Ty C, typical carcinoma; NEC, neuroendocrine carcinoma. Diamond implies overlap in Dx. Journal of Thoracic Oncology 2017 12, 334-346DOI: (10.1016/j.jtho.2016.12.004) Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions